Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Income from Continuing Operations over the past 3 years, most recently at 46942000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 46942000.0 for Q4 2025, down 106.26% from a year ago — trailing twelve months through Dec 2025 was 122185000.0 (up 10.98% YoY), and the annual figure for FY2025 was 121646000.0, up 11.8%.
  • Income from Continuing Operations for Q4 2025 was 46942000.0 at Tonix Pharmaceuticals Holding, down from 31836000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TNXP hit a ceiling of 15837000.0 in Q3 2024 and a floor of 77315000.0 in Q2 2024.
  • Median Income from Continuing Operations over the past 3 years was 27664000.0 (2023), compared with a mean of 31395916.67.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 166.59% in 2024 and later skyrocketed 64.62% in 2025.
  • Tonix Pharmaceuticals Holding's Income from Continuing Operations stood at 27322000.0 in 2023, then increased by 16.7% to 22759000.0 in 2024, then tumbled by 106.26% to 46942000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 46942000.0 (Q4 2025), 31836000.0 (Q3 2025), and 27353000.0 (Q2 2025) per Business Quant data.